Your browser doesn't support javascript.
loading
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.
Dicks, Ed M; Tyrer, Jonthan P; Ezquina, Suzana; Jones, Michelle; Baierl, John; Peng, Pei-Chen; Diaz, Michael; Goode, Ellen; Winham, Stacey J; Dörk, Thilo; Van Gorp, Toon; De Fazio, Ana; Bowtell, David; Odunsi, Kunle; Moysich, Kirsten; Pavanello, Marina; Campbell, Ian; Brenton, James D; Ramus, Susan J; Gayther, Simon A; Pharoah, Paul D P.
Affiliation
  • Dicks EM; Department of Public Health and Primary Care, University of Cambridge, UK.
  • Tyrer JP; Department of Public Health and Primary Care, University of Cambridge, UK.
  • Ezquina S; Department of Public Health and Primary Care, University of Cambridge, UK.
  • Jones M; Department of Biomedical Sciences, Cedars-Sinai Medical Centre, Los Angeles, USA.
  • Baierl J; Department of Computational Biomedicine, Cedars-Sinai Medical Centre, Los Angeles, USA.
  • Peng PC; Department of Computational Biomedicine, Cedars-Sinai Medical Centre, Los Angeles, USA.
  • Diaz M; Department of Biomedical Sciences, Cedars-Sinai Medical Centre, Los Angeles, USA.
  • Goode E; Mayo Clinic, Rochester, MN, USA.
  • Winham SJ; Mayo Clinic, Rochester, MN, USA.
  • Dörk T; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Van Gorp T; Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.
  • De Fazio A; Centre for Cancer Research, The Westmead Institute for Medical Research, The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW and Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Bowtell D; Cancer Genomics and Genetics and Women's Cancer Programs, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Odunsi K; University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
  • Moysich K; Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Pavanello M; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW, Sydney, NSW, Australia Center for Research in Immuno-Oncology, Albert Einstein Israelite Hospital, São Paulo, SP, Brazil.
  • Campbell I; Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Brenton JD; Department of Oncology, University of Cambridge, UK.
  • Ramus SJ; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW, Sydney, NSW, Australia Adult Cancer Program, Lowy Cancer Research Centre, University of NSW, Sydney, NSW, Australia.
  • Gayther SA; Department of Biomedical Sciences, Cedars-Sinai Medical Centre, Los Angeles, USA.
  • Pharoah PDP; Department of Computational Biomedicine, Cedars-Sinai Medical Centre, Los Angeles, USA.
medRxiv ; 2024 Apr 03.
Article in En | MEDLINE | ID: mdl-38633804
ABSTRACT
Rare, germline loss-of-function variants in a handful of genes that encode DNA repair proteins have been shown to be associated with epithelial ovarian cancer with a stronger association for the high-grade serous hiostotype. The aim of this study was to collate exome sequencing data from multiple epithelial ovarian cancer case cohorts and controls in order to systematically evaluate the role of coding, loss-of-function variants across the genome in epithelial ovarian cancer risk. We assembled exome data for a total of 2,573 non-mucinous cases (1,876 high-grade serous and 697 non-high grade serous) and 13,925 controls. Harmonised variant calling and quality control filtering was applied across the different data sets. We carried out a gene-by-gene simple burden test for association of rare loss-of-function variants (minor allele frequency < 0.1%) with all non-mucinous ovarian cancer, high grade serous ovarian cancer and non-high grade serous ovarian cancer using logistic regression adjusted for the top four principal components to account for cryptic population structure and genetic ancestry. Seven of the top 10 associated genes were associations of the known ovarian cancer susceptibility genes BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, MSH6 and PALB2 (false discovery probability < 0.1). A further four genes (HELB, OR2T35, NBN and MYO1A) had a false discovery rate of less than 0.1. Of these, HELB was most strongly associated with the non-high grade serous histotype (P = 1.3×10-6, FDR = 9.1×10-4). Further support for this association comes from the observation that loss of function variants in this gene are also associated with age at natural menopause and Mendelian randomisation analysis shows an association between genetically predicted age at natural menopause and endometrioid ovarian cancer, but not high-grade serous ovarian cancer.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: MedRxiv Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: MedRxiv Year: 2024 Document type: Article Country of publication: